NPRL2 is an independent prognostic factor of osteosarcoma

Cancer Biomarkers

Volumn 12, Issue 1, 2012, Pages 31-36

  Gao, Yuzhong ^a   Wang, Jian ^b   Fan, Guangyu ^c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b Second Hospital of Jinzhou City   (China)

^c China Medial University   (China)

Author keywords

Immunohistochemistry; NPRL2; Osteosarcoma; Prognosis

Indexed keywords

NPRL2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOCHONDROMA; OSTEOSARCOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADOLESCENT; BONE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; OSTEOCHONDROMA; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84872870057     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-120290     Document Type: Article

References (11)

1. Eftekhari F. Imaging Assessment of Osteosarcoma in Childhood and Adolescence: Diagnosis, Staging, and Evaluating Response in Chemotherapy. In: Jaffe N, Bruland OS, Bielack S. Pediatric and Adolescent Osteosarcoma. New York, NY: Springer, 2009, pp. 33-62.
2. Nishida H, Yamamoto N, Tanzawa Y, Tsuchiya H. Cryoimmunology formalignant bone and soft-tissue tumors. Int J Clin Oncol 16 (2011), 109-117.
3. Wajstaub S, Bezjak A, Howarth D, King MH, Catton CN. A radio-sensitive primary osteosarcoma in the lung. Int J Clin Oncol 16 (2011), 67-70.
4. Folio C, Zalacain M, Zandueta C, Ormazábal C, Sierrasesú maga L, San Julián M, de las Rivas J, Toledo G, Lecanda F, Patiño-García A. Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival. Cancer Biomark 10 (2011-2012), 35-41.
5. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60 (2000), 6116-6133.
6. Otani S, Takeda S, Yamada S, Sakakima Y, Sugimoto H, Nomoto S, Kasuya H, Kanazumi N, Nagasaka T, Nakao A. The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. J Surg Oncol 100 (2009), 358-363.
7. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125 (2009), 229-234.
8. Jawad MU, Scully SP. Classifications in Brief: Enneking Classification: Benign and Malignant Tumors of the Musculoskeletal System. Clin Orthop Relat Res 468 (2010), 2000-2002.
9. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 30 (2006), 445-451. (Pubitemid 44900550)
10. Bielack SS,Kempf-Bielack B,Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20 (2002), 776-790. (Pubitemid 34111386)
11. Kurata A, Katayama R, Watanabe T, et al. TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling. Cancer Sci 99 (2008), 1827-1834.